dc.contributorUniversidade Estadual Paulista (Unesp)
dc.contributorUniversidade de São Paulo (USP)
dc.date.accessioned2014-05-27T11:21:37Z
dc.date.available2014-05-27T11:21:37Z
dc.date.created2014-05-27T11:21:37Z
dc.date.issued2005-09-01
dc.identifierJournal of Periodontology, v. 76, n. 9, p. 1520-1525, 2005.
dc.identifier0022-3492
dc.identifierhttp://hdl.handle.net/11449/68399
dc.identifier10.1902/jop.2005.76.9.1520
dc.identifier2-s2.0-26944464177
dc.identifier2640929291808415
dc.description.abstractBackground: Cyclosporin (CsA) and tacrolimus (FK-506) are immunosuppressive drugs that specifically inhibit T-cell activation via calcineurin inhibition. Gingival overgrowth is a common side effect following the administration of CsA. The severity of gingival overgrowth seen in patients taking FK-506 is less than that observed with CsA. Little is known about the involvement of saliva in drug-induced gingival overgrowth. The purpose of this study was to investigate the salivary contents of tumor growth factor β1 (TGF-β1), epidermal growth factor (EGF), and interleukin-6 (IL-6) as well as the hystometry of gingival tissue obtained from rats treated with either FK-506 or CsA. Methods: For 30 or 60 days rats received daily subcutaneous injection doses of either CsA or FK-506 (10 mg/kg). The concentrations of TGF-β1, EGF, and IL-6 in saliva were determined by enzyme-linked immunosorbent assay, and after histological processing, the oral epithelium and connective tissue were assessed at the region of the lower first molars. Results: The levels of TGF-β1, EGF, and IL-6 in saliva were not significantly altered by any of the treatments after 30 days. After 60 days of treatment with CsA, gingival overgrowth and significant increase in salivary TGF-β1, EGF, and IL-6 concentrations were observed; no statistically significant changes were induced by FK-506. Conclusion: Within the limits of this experimental study, it can be concluded that CsA, but not FK-506, induced gingival overgrowth associated with an increase of the salivary levels of the cytokines TGF-β1, EGF, and IL-6.
dc.languageeng
dc.relationJournal of Periodontology
dc.relation3.392
dc.relation1,408
dc.rightsAcesso restrito
dc.sourceScopus
dc.subjectAnimal studies
dc.subjectCyclosporin A/adverse effects
dc.subjectGingival hyperplasia/etiology
dc.subjectGrowth factors, epidermal
dc.subjectGrowth factors, tumor β1
dc.subjectInterleukin-6
dc.subjectSaliva/analysis
dc.subjectTacrolimus/adverse effects
dc.subjectcyclosporin
dc.subjectcytokine
dc.subjectepidermal growth factor
dc.subjectinterleukin 6
dc.subjecttacrolimus
dc.subjecttransforming growth factor beta1
dc.subjectanimal experiment
dc.subjectanimal model
dc.subjectanimal tissue
dc.subjectconcentration response
dc.subjectconnective tissue
dc.subjectcontrolled study
dc.subjectenzyme linked immunosorbent assay
dc.subjectfibroblast
dc.subjectgingiva overgrowth
dc.subjecthistometry
dc.subjectmale
dc.subjectmolar tooth
dc.subjectmouth mucosa
dc.subjectnonhuman
dc.subjectrat
dc.subjectsalivation
dc.subjectAnimals
dc.subjectCyclosporine
dc.subjectCytokines
dc.subjectEpidermal Growth Factor
dc.subjectGingival Overgrowth
dc.subjectImmunosuppressive Agents
dc.subjectMale
dc.subjectRats
dc.subjectRats, Sprague-Dawley
dc.subjectSaliva
dc.subjectTacrolimus
dc.subjectTransforming Growth Factor beta
dc.subjectTransforming Growth Factor beta1
dc.titleCyclosporin but not tacrolimus significantly increases salivary cytokine contents in rats
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución